Ridabu, Norway

Pål Aukrust

USPTO Granted Patents = 3 



Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2007-2012

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Pål Aukrust: Innovator in Immunology

Introduction

Pål Aukrust is a notable inventor based in Ridabu, Norway. He has made significant contributions to the field of immunology, particularly in the treatment and prevention of diseases such as AIDS. With a total of two patents to his name, Aukrust's work is recognized for its innovative approaches to complex medical challenges.

Latest Patents

Aukrust's latest patents include methods for treating and preventing AIDS using COX-2 inhibitors. This invention provides a method for treating or preventing disorders characterized by immunodeficiency, such as HIV. The method involves administering a COX-2 inhibitor or its derivatives, including diisopropylfluorophosphate, L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib, or nimesulide. Additionally, he has developed pharmaceutical compositions that are useful for treating immunosuppressive diseases, which contain compounds capable of inhibiting cAMP-dependent protein kinase A (PKA).

Career Highlights

Aukrust is associated with Lauras AS, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on the treatment of serious health conditions.

Collaborations

Some of his notable coworkers include Kjetil Taskén and Einar Martin Aandahl, who have collaborated with him on various projects in the field of immunology.

Conclusion

Pål Aukrust's contributions to medical science, particularly in immunology, highlight his role as an innovative inventor. His patents reflect a commitment to developing effective treatments for serious diseases, showcasing the importance of research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…